Recent research and clinical trials have shown strong correlation of breast cancer responses to neoadjuvant therapies with survival and prognosis, mainly in triple negative and HER2-overexpressing breast carcinoma [4]. The gene discussed is ERBB2; the disease is breast carcinoma.